Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.

<< Back to News

11/30/18 SR -- Renflexis: preferred inFLIXimab product - starting Monday, December 3rd

From: Samantha Rustamov
To: Pharmacists
Sent: Friday, November 30, 2018 2:35:12 PM
Subject: Renflexis: preferred inFLIXimab product - starting Monday, December 3rd

Pharmacy will begin dispensing Renflexis, an inFLIXimab biosimilar, which was classified as formulary restricted in July 2018 . It is judged to be interchangeable with Remicade/Inflectra and has the same restrictions. inFLIXimab product selection will depend on comparative costs of products and reimbursement issues. Preferred product will likely change over time and the FORMWeb entry will be updated (see below).

To select this product in iCare, please use the "RENFLEXIS ___ MG IVPB" medication entry. Dose rounding will continue to be to the nearest 50 mg for patients 18 years and over. We will keep a small supply of Remicade for any " No Substitution " orders.

Samantha Rustamov, Pharm.D., BCPS
Supervisor, Pharmacy Professional Services Huntsville Hospital Department of Pharmacy






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.